Morgan Stanley’s Briacell Therapeutics BCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTX
CCC
SM
IAM
HF
LCM
FDCDDQ
Morgan Stanley's BCTX Position: Q2 2026 in Review
Morgan Stanley reduced its Briacell Therapeutics (BCTX) stake by 66% in Q2 2026, selling an estimated $7.32K and leaving 1,033 shares worth $3.35K. The position accounts for ﹤0.01% of the portfolio, ranked #7301.
Morgan Stanley first reported a position in BCTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $594K in Q3 2023. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.
- Morgan Stanley held 1,033 shares of Briacell Therapeutics worth $3.35K as of Q2 2026.
- Morgan Stanley sold 1,988 Briacell Therapeutics shares in Q2 2026, an estimated $7.32K.
- Briacell Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7301 holding.
- Morgan Stanley first reported a position in Briacell Therapeutics in Q2 2021 and has held it in 21 quarters since.
- Morgan Stanley's Briacell Therapeutics position peaked at $594K in Q3 2023.
- 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.